GO:0004908 interleukin-1 receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004908 interleukin-1 receptor activity describes the molecular function of combining with interleukin-1 cytokines to initiate a change in cell activity.
• The interleukin-1 system includes the ligands IL-1α and IL-1β, the signaling receptor IL-1R1, the decoy receptor IL-1R2, and the natural antagonist IL-1RA.
• IL-1 receptor activity is central to innate immunity and inflammation, and dysregulation is linked to autoinflammatory diseases, gout, and traumatic brain injury.
• The IL-1 receptor family shares a conserved Toll/interleukin-1 receptor (TIR) domain that mediates intracellular signaling and is found across animals, plants, and bacteria.
• IL-33 signals through the IL-1 receptor-related protein ST2, illustrating how GO:0004908 encompasses a broader family of IL-1-like cytokine receptors.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect which receptor components are causally involved in IL-1-driven disease.
Description
Interleukin-1 receptor activity (GO:0004908) is the molecular function of binding interleukin-1 cytokines and transmitting a signal that changes cellular behavior. Interleukin-1 is produced mainly by activated macrophages and is a master mediator of the inflammatory response. The receptor activity is therefore a critical node linking innate immune sensing to downstream transcriptional programs. Researchers study GO:0004908 to understand how inflammatory signals are initiated, amplified, and resolved in health and disease. The IL-1 receptor family is evolutionarily ancient, with Toll/interleukin-1 receptor (TIR) domains present in plants and bacteria as well as mammals. This broad conservation makes interleukin-1 receptor activity a paradigm for signal transduction across kingdoms. In humans, the canonical IL-1 receptor type 1 (IL-1R1) binds IL-1α and IL-1β and recruits the co-receptor IL-1RAcP to trigger NF-κB and MAPK pathways. A decoy receptor, IL-1R2, and a secreted antagonist, IL-1RA, tightly regulate the system. Dysregulated interleukin-1 receptor activity contributes to autoinflammatory syndromes, gout, and neuroinflammation after traumatic brain injury. Consequently, tools that precisely manipulate receptor genes are in high demand for mechanistic and translational research.
interleukin-1 receptor activity At A Glance
| GO ID | GO:0004908 |
|---|---|
| GO term | interleukin-1 receptor activity |
| Ontology | molecular_function |
| Synonym | IL-1R, IL-1 receptor activity |
| Definition | Combining with interleukin-1 to initiate a change in cell activity; interleukin-1 is produced mainly by activated macrophages and is involved in the inflammatory response. |
| Major function | Binding IL-1 family cytokines and initiating intracellular signals that drive inflammatory and immune responses. |
| Representative receptors | IL-1R1, IL-1R2, IL-1RAcP, ST2 (IL1RL1) |
| Key ligands | IL-1α, IL-1β, IL-33 |
| Conserved domain | Toll/interleukin-1 receptor (TIR) domain |
What Is GO:0004908?
According to the Gene Ontology, GO:0004908 interleukin-1 receptor activity is a molecular function defined as combining with interleukin-1 to initiate a change in cell activity. Interleukin-1 is produced mainly by activated macrophages and is involved in the inflammatory response. In practice, this means the receptor protein binds an IL-1 family cytokine and, upon binding, triggers intracellular signaling that alters gene expression, cytokine release, or cell survival. The term covers receptors such as IL-1R1 and related family members that recognize IL-1-like cytokines, including the ST2 receptor for IL-33.
Why Is interleukin-1 receptor activity Important in Cell Biology?
Interleukin-1 receptor activity is a central control point for inflammation and innate immunity, and its dysregulation underlies a wide range of human diseases. Because IL-1 is produced mainly by activated macrophages, receptor activity directly translates macrophage sensing into systemic inflammatory responses. The clinical relevance is underscored by the success of IL-1 receptor antagonist (IL-1RA) as a therapy for traumatic brain injury and other inflammatory conditions. Moreover, the discovery that IL-33 signals through the IL-1 receptor-related protein ST2 expanded the family and linked GO:0004908 to type 2 immunity. The conserved TIR domain shared by IL-1 receptors and Toll-like receptors makes this activity a model for understanding innate immune signal transduction. Therefore, precise genetic models of interleukin-1 receptor activity are essential for target validation and drug development.
• IL-1 receptor activity initiates NF-κB and MAPK signaling, driving expression of inflammatory cytokines and chemokines.
• It is a validated therapeutic target; IL-1RA is used to treat traumatic brain injury and other inflammatory diseases.
• Gout-associated uric acid crystals activate the NALP3 inflammasome, leading to IL-1β release and receptor activation.
• IL-33 signals via the IL-1 receptor-related protein ST2, linking GO:0004908 to T helper type 2 responses.
• TIR domain-containing proteins in plants and bacteria share mechanistic features with IL-1 receptors, informing comparative studies.
• Dysregulated IL-1 receptor activity is implicated in autoinflammatory syndromes, arthritis, and neuroinflammation.
• The decoy receptor IL-1R2 and antagonist IL-1RA provide endogenous negative regulation of the activity.
• Knockout and knock-in models of IL-1R1 and IL-1RAcP are widely used to test causality in inflammatory disease.
• Interleukin-1 receptor activity is a biomarker and target in cancer-related inflammation and tumor microenvironment studies.
• Understanding GO:0004908 aids development of small-molecule and biologic inhibitors of IL-1 signaling.
What Happens During interleukin-1 receptor activity?
Ligand binding and receptor engagement
In simple terms: First, the IL-1 cytokine docks onto its receptor on the cell surface.
Interleukin-1 receptor activity begins when IL-1α or IL-1β binds the extracellular domain of IL-1R1. This binding is highly specific and is the defining event of GO:0004908. The decoy receptor IL-1R2 can also bind IL-1 but lacks a signaling domain, thereby sequestering the ligand. The natural antagonist IL-1RA competes with IL-1 for IL-1R1 binding without activating the receptor.
Co-receptor recruitment and TIR domain assembly
In simple terms: After the cytokine binds, a second receptor joins in, and their intracellular tails come together.
Ligand-bound IL-1R1 recruits the co-receptor IL-1RAcP, forming a heterodimeric complex. This brings the intracellular Toll/interleukin-1 receptor (TIR) domains of both receptors into close proximity. TIR domain assembly is a conserved feature of IL-1 receptor signaling and is also found in plant and bacterial immune proteins. The TIR domain serves as a scaffold for downstream adaptor proteins.
Adaptor recruitment and signaling cascade
In simple terms: The clustered tails then recruit adaptor proteins that switch on the cell's alarm system.
The TIR domains of the receptor complex recruit the adaptor MyD88, which nucleates a signaling platform. This leads to activation of IRAK kinases and TRAF6, culminating in NF-κB and MAPK activation. The outcome is transcriptional induction of inflammatory genes, a hallmark of interleukin-1 receptor activity. This cascade is tightly controlled to prevent excessive inflammation.
Negative regulation and signal termination
In simple terms: The cell also has brakes to stop the signal so inflammation does not run out of control.
IL-1RA is a secreted antagonist that binds IL-1R1 and prevents IL-1 from activating the receptor. IL-1R2 acts as a decoy receptor, trapping IL-1 and reducing available ligand. Additionally, soluble forms of IL-1R2 and IL-1RAcP can modulate signaling in the extracellular space. These regulatory mechanisms are critical for resolving inflammation and are exploited therapeutically.
IL-33 and the ST2 receptor pathway
In simple terms: A related cytokine, IL-33, uses a similar receptor to drive allergy-type immune responses.
IL-33 is an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 (IL1RL1). This interaction induces T helper type 2-associated cytokines, expanding the biological scope of GO:0004908. The ST2 pathway demonstrates that interleukin-1 receptor activity is not limited to classical IL-1α/β signaling. Researchers studying GO:0004908 must therefore consider family members beyond IL-1R1.
Key Genes Involved in GO:0004908 interleukin-1 receptor activity
The following genes encode the receptors, ligands, and signaling components that collectively mediate interleukin-1 receptor activity (GO:0004908).
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1R1 | Primary signaling receptor for IL-1α and IL-1β | Knockout models define canonical IL-1 receptor activity |
| IL1R2 | Decoy receptor that sequesters IL-1 | Overexpression studies test negative regulation |
| IL1RAP | Co-receptor required for IL-1R1 signaling | Knockout abolishes downstream NF-κB activation |
| IL1RN | Encodes IL-1 receptor antagonist (IL-1RA) | Therapeutic use in traumatic brain injury |
| IL1A | Ligand IL-1α, produced by macrophages | Point mutations probe binding specificity |
| IL1B | Ligand IL-1β, major pyrogenic cytokine | Knockout reduces inflammatory disease severity |
| IL1RL1 | ST2 receptor for IL-33 | Links GO:0004908 to type 2 immunity |
| IL33 | IL-1-like cytokine signaling via ST2 | Induces T helper type 2 cytokines |
| MYD88 | Adaptor recruited to TIR domains | Essential for IL-1 receptor signaling |
| IRAK4 | Kinase activated downstream of MyD88 | Target for anti-inflammatory drugs |
| TRAF6 | E3 ligase mediating NF-κB activation | Knockout blocks IL-1-induced signaling |
| NFKB1 | Transcription factor driving inflammatory genes | Readout of IL-1 receptor activity |
| NLRP3 | Inflammasome activating IL-1β | Gout-associated crystals activate NLRP3 |
| TIRAP | TIR domain-containing adaptor protein | Modulates IL-1 receptor signaling |
| SIGIRR | Negative regulator of IL-1 receptor family | Overexpression dampens inflammation |
| IL1RAPL1 | IL-1 receptor accessory protein-like 1 | Neuronal functions linked to IL-1 family |
| PELI1 | E3 ubiquitin ligase regulating IRAK | Feedback control of IL-1 signaling |
How Is interleukin-1 receptor activity Regulated?
Interleukin-1 receptor activity is regulated at multiple levels. The secreted antagonist IL-1RA competes with IL-1 for receptor binding, providing a reversible brake on signaling. The decoy receptor IL-1R2 sequesters IL-1 and reduces effective ligand concentration. Intracellularly, negative regulators such as SIGIRR and PELI1 dampen TIR domain signaling to prevent excessive inflammation. The NLRP3 inflammasome controls the maturation and release of IL-1β, thereby regulating ligand availability for GO:0004908. In the context of traumatic brain injury, administration of IL-1RA reduces neuroinflammation, demonstrating that the pathway is amenable to therapeutic regulation. Additionally, TIR domain-containing proteins in plants and bacteria exhibit NAD-RNA decapping activity, suggesting ancient regulatory mechanisms that may inform studies of IL-1 receptor signaling.
interleukin-1 receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL1B | Gout and autoinflammatory flares | NLRP3 inflammasome activation in macrophages |
| IL1RN | Traumatic brain injury neuroinflammation | IL-1RA administration in animal models |
| IL1RL1 | Asthma and type 2 inflammation | ST2 knockout or overexpression in T cells |
| IL1R1 | Cancer-related inflammation | IL-1R1 knockout in tumor models |
| MYD88 | Innate immune signaling defects | MyD88 knockout macrophages |
Autoinflammatory and gout-associated inflammation
Gout-associated uric acid crystals activate the NALP3 inflammasome, leading to IL-1β processing and release. The secreted IL-1β then binds IL-1R1, activating GO:0004908 and amplifying inflammation. This mechanism is central to gout flares and other autoinflammatory conditions. Targeting interleukin-1 receptor activity with antagonists such as IL-1RA is a validated therapeutic strategy.
Traumatic brain injury and neuroinflammation
After traumatic brain injury, IL-1 is rapidly released and drives secondary neuroinflammation via interleukin-1 receptor activity. Clinical and preclinical studies have tested IL-1 receptor antagonist as a therapy to reduce brain damage and improve outcomes. These studies highlight GO:0004908 as a druggable node in acute neurotrauma. Genetic models of IL-1R1 and IL-1RAcP are used to dissect the contribution of receptor signaling to injury progression.
Type 2 immunity and allergic inflammation
IL-33 signals through the IL-1 receptor-related protein ST2, a member of the interleukin-1 receptor family. This pathway induces T helper type 2-associated cytokines and is implicated in asthma and allergy. Thus, GO:0004908 extends beyond classical IL-1α/β biology to include IL-33-driven responses. Researchers studying allergic inflammation often target ST2 or its ligand to modulate this branch of the receptor family.
Cancer-related inflammation
Chronic inflammation driven by interleukin-1 receptor activity can promote tumor progression and immunosuppression. IL-1 signaling in the tumor microenvironment influences angiogenesis, immune cell recruitment, and metastasis. Consequently, inhibitors of IL-1 receptor activity are being explored as adjuncts to cancer immunotherapy. Preclinical models with IL-1R1 knockout or overexpression help define the causal role of GO:0004908 in cancer.
From interleukin-1 receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL-1R1 mediate inflammatory signaling in macrophages? | IL1R1 knockout cell line |
| Can a point mutation in IL-1R1 abolish ligand binding? | Point-mutation knock-in of IL1R1 |
| What is the effect of IL-1RA overexpression on neuroinflammation? | IL1RN overexpression in neuronal cells |
| How does ST2 contribute to type 2 cytokine production? | IL1RL1 knockout or tagged knock-in |
| Does IL-1R2 act as a decoy in vivo? | IL1R2 overexpression or knockout |
| Can TIR domain mutations disrupt downstream NF-κB activation? | Point-mutation knock-in of IL1RAP |
How to Study the interleukin-1 receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of receptor function | Validate IL1R1 dependence |
| RNA-seq | Transcriptional changes | NF-κB target gene profiling |
| ELISA | Secreted IL-1β and cytokines | Inflammasome activation |
| Western blot | Phosphorylation of signaling intermediates | IRAK/TRAF6 activation |
| Luciferase reporter | NF-κB transcriptional activity | High-throughput screening |
| Live-cell imaging | Receptor trafficking and internalization | Dynamic signaling studies |
| Proteomics | Protein interaction networks | TIR domain interactome |
| Flow cytometry | Surface IL-1R1 expression | Cell population analysis |
CRISPR knockout and knock-in for receptor genes
CRISPR-Cas9 knockout of IL1R1, IL1RAP, or MYD88 provides definitive loss-of-function models to test interleukin-1 receptor activity. Knock-in of point mutations in the ligand-binding domain or TIR domain allows structure-function analysis. These models are essential for target validation in inflammatory disease.
Transcriptional and proteomic readouts
RNA-seq after IL-1 stimulation measures the transcriptional output of GO:0004908, including NF-κB target genes. Proteomics can quantify cytokine secretion and signaling intermediate phosphorylation. These methods link receptor activity to downstream cellular programs.
Inflammasome and cytokine release assays
ELISA and Western blotting for mature IL-1β assess inflammasome-dependent ligand production. Macrophage stimulation with uric acid crystals or LPS/ATP recapitulates gout-associated activation. Such assays connect upstream inflammasome activation to interleukin-1 receptor activity.
Imaging and reporter systems
NF-κB luciferase reporters and fluorescent tagging of IL-1R1 enable real-time monitoring of receptor activation. Live-cell imaging can track receptor internalization and trafficking. These tools are valuable for high-content screening of modulators.
How CRISPR Can Be Used to Study GO:0004908 interleukin-1 receptor activity
Knockout
CRISPR knockout of IL1R1, IL1RAP, or MYD88 abolishes interleukin-1 receptor activity and is used to test causal roles in inflammation. These models are particularly valuable for validating drug targets in traumatic brain injury and autoinflammatory disease.
Point Mutation
Point mutations in the ligand-binding domain of IL-1R1 or in the TIR domain of IL-1RAcP can dissect binding versus signaling functions. Such knock-in models reveal residues critical for GO:0004908 activity.
Knock-in
Knock-in of epitope tags or fluorescent proteins into IL1R1 or IL1RL1 enables tracking of receptor expression and localization. This approach helps correlate receptor abundance with signaling output.
Overexpression
Overexpression of IL1RN (IL-1RA) or IL1R2 can suppress interleukin-1 receptor activity and is used to model therapeutic antagonism. Overexpression of ST2 can enhance IL-33-driven type 2 responses.
How EDITGENE Supports interleukin-1 receptor activity Research
Researchers studying interleukin-1 receptor activity-related genes often need to determine whether a candidate gene is causally involved in inflammatory signaling or disease progression. EDITGENE provides publication-grade CRISPR models and bioinformatics services to accelerate that discovery process.
Contact EDITGENE today to design your custom CRISPR model for interleukin-1 receptor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IL18R1 Knockout HEK293 Cell Line | EDJ-KQ244 | Human | 8809 | Details Get a Quote |
| IL1R1 Knockout HEK293 Cell Line | EDJ-KQ568 | Human | 3554 | Details Get a Quote |
| IL1RAP Knockout HEK293 Cell Line | EDJ-KQ678 | Human | 3556 | Details Get a Quote |
| IL1RL2 Knockout HEK293 Cell Line | EDJ-KQ5680 | Human | 8808 | Details Get a Quote |
| IL1R2 Knockout HEK293 Cell Line | EDJ-KQ6135 | Human | 7850 | Details Get a Quote |
| IL1RL1 Knockout HEK293 Cell Line | EDJ-KQ6485 | Human | 9173 | Details Get a Quote |
| IL1RAPL2 Knockout HEK293 Cell Line | EDJ-KQ8503 | Human | 26280 | Details Get a Quote |
| IL1R1 Knockout A-549 Cell Line | EDJ-KQ18961 | Human | 3554 | Details Get a Quote |
| IL1R1 Knockout HCT 116 Cell Line | EDJ-KQ18962 | Human | 3554 | Details Get a Quote |
| IL1R1 Knockout HeLa Cell Line | EDJ-KQ18963 | Human | 3554 | Details Get a Quote |
| IL1RAP Knockout A-549 Cell Line | EDJ-KQ19211 | Human | 3556 | Details Get a Quote |
| IL1RAP Knockout HCT 116 Cell Line | EDJ-KQ19212 | Human | 3556 | Details Get a Quote |
| IL1RAP Knockout HeLa Cell Line | EDJ-KQ19213 | Human | 3556 | Details Get a Quote |
| IL18R1 Knockout A-549 Cell Line | EDJ-KQ21064 | Human | 8809 | Details Get a Quote |
| IL18R1 Knockout HCT 116 Cell Line | EDJ-KQ21065 | Human | 8809 | Details Get a Quote |
Displaying Records 1 To 15 Of 28 Records
Frequently Asked Questions About interleukin-1 receptor activity
What is interleukin-1 receptor activity?
It is the molecular function defined by GO:0004908, in which a receptor binds interleukin-1 to initiate a change in cell activity, typically triggering inflammatory signaling.
What genes are involved in interleukin-1 receptor activity?
Key genes include IL1R1, IL1R2, IL1RAP, IL1RN, IL1A, IL1B, IL1RL1, MYD88, IRAK4, and TRAF6.
What is the GO ID for interleukin-1 receptor activity?
The Gene Ontology ID is GO:0004908.
How does IL-1 receptor signaling work?
IL-1 binds IL-1R1, which recruits IL-1RAcP; their TIR domains then recruit MyD88 and activate NF-κB and MAPK pathways.
What diseases are linked to interleukin-1 receptor activity?
Gout, autoinflammatory syndromes, traumatic brain injury, asthma, and cancer-related inflammation are linked to this activity.
What is the role of IL-1RA in disease?
IL-1RA is a natural antagonist of IL-1R1 and has been tested as a therapy for traumatic brain injury and other inflammatory conditions.
How is IL-33 related to interleukin-1 receptor activity?
IL-33 is an IL-1-like cytokine that signals through the IL-1 receptor-related protein ST2, inducing T helper type 2 cytokines.
What experimental models study interleukin-1 receptor activity?
CRISPR knockout, knock-in, point-mutation, and overexpression models of IL1R1, IL1RAP, and MYD88 are commonly used.
What is the TIR domain?
The Toll/interleukin-1 receptor domain is a conserved signaling module in IL-1 receptors and related proteins across species.
How can CRISPR help study interleukin-1 receptor activity?
CRISPR enables precise knockout or mutation of receptor genes to test their causal role in inflammatory signaling and disease.
Conclusion
Interleukin-1 receptor activity (GO:0004908) is a fundamental molecular function that translates IL-1 cytokine signals into inflammatory and immune responses. Its dysregulation is implicated in gout, neuroinflammation, autoinflammatory diseases, and cancer-related inflammation. The conserved TIR domain and family members such as ST2 highlight its broad biological and evolutionary significance. CRISPR-based models are indispensable for dissecting the causal roles of receptor components and for validating therapeutic targets. EDITGENE offers comprehensive services to support such research with precision and scale.
References
- 1. Schmitz J et al.. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.. Immunity 23(5):479-90 PMID: 16286016
- 2. Lindblad C et al.. 2023. Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury.. Neurotherapeutics 20(6):1508-1528 PMID: 37610701
- 3. Dinarello CA. 1997. Interleukin-1.. Cytokine Growth Factor Rev 8(4):253-65 PMID: 9620641
- 4. Wang X et al.. 2024. Toll/interleukin-1 receptor (TIR) domain-containing proteins have NAD-RNA decapping activity.. Nat Commun 15(1):2261 PMID: 38480720
- 5. Martinon F et al.. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome.. Nature 440(7081):237-41 PMID: 16407889
- 6. Stylianou E et al.. 1998. Interleukin-1.. Int J Biochem Cell Biol 30(10):1075-9 PMID: 9785472
- 7. Dinarello CA. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist.. Int Rev Immunol 16(5-6):457-99 PMID: 9646173
- 8. Yu H et al.. 2024. Activation of a helper NLR by plant and bacterial TIR immune signaling.. Science 386(6728):1413-1420 PMID: 39509471
